Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 222

The DOI matches its Crossref record.

Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease: Evidence and Mechanisms of Action

Eddy, Allison A., Fogo, Agnes B.·2006·Journal of the American Society of Nephrology

Abstract

In 1984, Loskutoff et al. (1) purified plasminogen activator inhibitor-1 (PAI-1) from conditioned media of cultured endothelial cells. This 50-kd glycoprotein is the primary physiologic inhibitor of the serine proteases tissue-type and urokinase-type plasminogen activators (tPA and uPA, respectively). It now is known to mediate important biologic activities that extend far beyond fibrinolysis through interactions with its co-factor, vitronectin (also known as protein S), and with the urokinase receptor (uPAR) and its co-receptors (2,3). Plasma PAI-1 levels increase in response to stress as an acute-phase protein. Usually present in trace amounts, plasma PAI-1 levels increase in several chronic inflammatory states that are associated with chronic kidney disease (CKD), and it may contribute to the pathogenesis of the accelerated vascular disease in this patient population (4–7). Liver and adipose tissue seem to be the primary sources of plasma PAI-1 (8,9). Other inhibitors of plasminogen activation exist; protease nexin-1 and α-2 anti-plasmin can be produced by the kidney. Although PAI-1 normally is not produced in kidneys, synthesis by both resident and intrarenal inflammatory cells occurs in several acute and chronic disease states (Table 1). In the past decade, a growing body of experimental evidence that has derived largely from animal models supports the view that PAI-1 is a powerful fibrosis-promoting molecule and is a promising therapeutic target for new drugs and biologics to combat the current CKD epidemic (Table 2). Exactly how PAI-1 promotes renal fibrosis is not understood completely. Recent studies suggest that in addition to its ability to inhibit serine protease activity within vascular and extracellular compartments, PAI-1 directly modulates cellular behavior, leading to a vicious cycle of inflammatory cell recruitment, fibroblast activation, and scar tissue accumulation. PAI-1 Is Present in Most Aggressive Kidney Diseases Acute/Thrombotic Diseases Thrombotic microangiopathy (TMA) is a pathologic lesion that is characterized by fibrin deposition in the microvasculature, often involving glomeruli and renal arterioles. TMA characterizes renal diseases that are caused by hemolytic uremic syndrome, preeclampsia, scleroderma, malignant hypertension, and the antiphospholipid antibody syndrome. Glomerular PAI-1 deposition is a feature of TMA (10). In children who have Escherichia coli 0157:H7 infection and later develop hemolytic uremic syndrome (11), plasma PAI-1 levels increase before the onset of renal disease. Plasma PAI-1 activity correlates with renal disease severity and long-term outcome (12–15). One pediatric study found that PAI-1 activity also increases during acute renal failure of other causes (16). Animal hemolytic uremic syndrome models that should provide specific insights into the pathogenetic role of PAI-1 are under development (17,18). The extent to which renal PAI-1 is produced locally or derived from the plasma pool has not been determined. PAI-1 expression is a feature of preeclampsia (19) and scleroderma, although experimental data suggest that PAI-1 is not essential in the latter (20,21). Radiation nephropathy is characterized in its early phase by TMA with PAI-1 generation, and it often progresses to sclerosis. Angiotensin or aldosterone inhibition reduces PAI-1 levels and the severity of glomerular sclerosis in experimental radiation nephropathy (22,23). Crescentic Glomerulonephritis Crescents develop as a result of segmental breaks of the glomerular basement membrane (GBM), often in association with fibrinoid necrosis. In human crescentic glomerulonephritis, PAI-1 is detected both in areas of glomerular necrosis and in crescents (24,25). Parietal epithelial cells are a source of PAI-1 and uPA in human crescentic glomerulonephritis (26). In experimental models of anti-GBM crescentic nephritis, PAI-1 is produced, whereas tPA levels are suppressed, leading to decreased net glomerular fibrinolytic activity and prolonged fibrin deposition (27). A functional role for PAI-1 in the pathogenesis of anti-GBM crescentic glomerulonephritis was established by elegant studies in genetically engineered mice (Table 2) (28). The PAI-1−/− mice developed fewer glomerular crescents and glomerular fibrin deposits and reduced collagen accumulation long term. In contrast, mice that were engineered to overexpress PAI-1 formed more crescents along with more extensive fibrin deposits and extensive collagen accumulation. Genetic manipulations that reduce serine protease activity, either plasminogen deficiency or combined uPA and tPA deficiency, also lead to aggressive injury with more extensive crescents, necrosis, and fibrin deposition (29). Isolated tPA deficiency causes glomerular injury that is intermediate between wild-type and combination PA knockout mice, whereas isolated uPA deficiency results in fewer glomerular macrophages, but, otherwise, disease severity is similar to the wild-type mice,

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2006050503

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 222

Metadata

Authors
Eddy, A. A., & Fogo, A. B.
Venue
Journal of the American Society of Nephrology
Published
2006-11
Volume
17
Issue
11
Pages
2999-3012
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2148081733
Cited by
222
References
0
FWCI
4.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease: Evidence and Mechanisms of Action. https://app.cochat.ai/papers/10.1681/asn.2006050503
The paper
Eddy, A. A., & Fogo, A. B. (2006). Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease: Evidence and Mechanisms of Action. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2006050503

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.